Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Beni-Suef University
One hundred and seven women with metastatic breast cancer (MBC) are randomly assigned to either a metformin (500 mg twice daily) or placebo (placebo) group during chemotherapy. All patients followed the standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI). Blood IGF-1 levels were measured at the start of treatment (baseline) and again six months later.
Age
18–any
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Female patients with MBC
patients older than 18
nondiabetic patients
patients who received only chemotherapy
You may not be if
patients with non-metastatic breast cancer
patients receiving hormonal therapy or radiotherapy
patients with diabetes
history of cardiac diseases
hypersensitivity, or allergy to metformin.
Clareo Health | IGF Level in Breast Cancer Patients Treated With Metformin
